BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Danaher Reports Third Quarter 2017 Results

  Danaher today announced results for the third quarter of 2017.

  October 19, 2017

   · 

  29 min read
• FDA

  BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy

  BioLife Solutions today announced that its customer Kite Pharma has received US FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.

  October 19, 2017

   · 

  3 min read
• Policy

  Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim)

  Prometic today announced that Health Canada has granted priority review status for the NDS the company plans to file for its plasminogen replacement therapy (RyplazimTM) for the treatment of patients with plasminogen deficiency.

  October 19, 2017

   · 

  4 min read
• Business

  Quest Diagnostics Reports Third Quarter 2017 Financial Results, Updates 2017 Financial Guidance and Reaffirms Long Term Outlook

  Quest Diagnostics announced today financial results for the third quarter ended September 30, 2017.

  October 19, 2017

   · 

  58 min read
• Business

  Johnson Announces Quarterly Dividend for Fourth Quarter 2017

  J&J today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2017 of $0.84 per share on the company’s common stock.

  October 19, 2017

   · 

  1 min read
• Business

  Teleflex Announces Third Quarter 2017 Earnings Conference Call Information

  Teleflex announced today that financial results for the third quarter 2017 will be released before market open on Thursday, November 2, 2017.

  October 19, 2017

   · 

  1 min read
• Drug Development

  Dynavax Initiates Clinical Trial In Non-Small Cell Lung Cancer With A Novel Inhaled TLR9 Agonist In Combination With Anti-PD-1 Therapy

  Dynavax Technologies Corporation announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC).

  October 19, 2017

   · 

  3 min read
• Drug Development

  Biscayne Neurotherapeutics Reports Successful Phase Ib Clinical Trial Results For Its Novel Antiepileptic Agent

  Biscayne Neurotherapeutics announced results from a Phase 1b trial of its novel antiepileptic compound, BIS-001ER.

  October 19, 2017

   · 

  4 min read
• Business

  Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer

  Cellect announced today that it has nominated Dr. Ronit Bakimer-Kleiner as Chief Development Officer replacing Dr. Yaron Pereg.

  October 19, 2017

   · 

  4 min read
• Business

  Second Sight Announces Appointments Of Frank Vandeputte As Vice President And General Manager, EMEA And Asia Pacific; Gregoire Cosendai As Vice President, Clinical Affairs

  Second Sight Medical Products announced the appointment of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific, where he will lead all commercial activities for the Company outside of North America.

  October 19, 2017

   · 

  7 min read